Grace Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.62 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $2.04Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $42.9M Enterprise Value $29.2M Shares Outstanding 21M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Grace Therapeutics is a late-stage biopharmaceutical company focused on rare and orphan diseases. The investment thesis centers on its lead clinical asset, GTx-104, an intravenous formulation of nimodipine designed to treat aneurysmal subarachnoid hemorrhage (aSAH). Although the FDA issued a Complete Response Letter (CRL) in April 2026, the setback was entirely non-clinical, focusing on CMC, non-clinical toxicology, and CMO cGMP compliance. The pivotal Phase 3 STRIVE-ON safety trial successfully met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension compared to oral nimodipine, alongside superior dose intensity and improved functional outcomes. With a Type A meeting scheduled to clarify the resubmission path and a cash runway of $17.0 million extending into 2027, Grace is well-positioned to resolve these regulatory hurdles and address a highly concentrated, high-value market with no meaningful innovation in over 40 years. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$4.09 Mean target$6.06 High · most bullish analyst$8.03 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.79 The FDA requires additional non-clinical toxicology studies or a new manufacturing site, significantly delaying the NDA resubmission. The cash runway of 12 months becomes depleted, forcing highly dilutive equity financing or operational curtailment of pipeline assets (GTx-102 and GTx-101). Base CaseCentral scenario $5.99 The FDA Type A meeting successfully clarifies the path forward, confirming that the cited CMC and non-clinical issues can be resolved without new clinical trials. Grace resubmits the NDA for GTx-104 in late 2026 or early 2027, leading to FDA approval. The company leverages its strong clinical data from the STRIVE-ON trial to rapidly displace oral nimodipine as the standard of care in the concentrated U.S. hospital market, driving significant valuation upside. Bull CaseUpside scenario $8.00 The FDA Type A meeting confirms a rapid path to approval. The NDA is resubmitted in late 2026 and approved by mid-2027. GTx-104 achieves rapid market penetration in U.S. hospitals, capturing over 40% of the market and driving peak sales above $100M, leading to a valuation of $8.00+ per share. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |